CSL集团旗下拥有两大核心业务,分别是专注于血浆衍生疗法的CSL Behring(杰特贝林)和专注于流感疫苗的CSL Seqirus。最新发布的财报显示,CSL集团将降低固定成本在总支出中的占比,并实施多项举措以提高研发管线效率,包括整合研发业务布局。在近期公布的第二季度财报中,制药行业正迎来新一轮结构性调整。默沙东、辉瑞、拜耳及诺和诺德等多家巨头相继宣布裁员与成本削减计划,其中仅默沙东一家便裁撤...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.